Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Still A Chance For Broad Use Of Teva's Reslizumab?

This article was originally published in Scrip

Executive Summary

The FDA's Pulmonary-Allergy Drugs Advisory Committee on Dec. 9 threw its support behind Teva Pharmaceutical Industries Ltd.'s experimental asthma drug reslizumab as a treatment for adults with severe asthma, but said there were not enough data about whether the drug is safe and effective in adolescents 12-17 years.